Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: Effects of dose, diagnosis, age, sex, smoking, and comedication

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 750-759

  Theisen, Frank M ^a   Haberhausen, Michael ^a   Schulz, Eberhard ^b   Fleischhaker, Christian ^b   Clement, Hans Willi ^b   Heinzel Gutenbrunner, Monika ^a   Remschmidt, Helmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CYP450; Drug interactions; HPLC; Interindividual variability; Therapeutic drug monitoring

Indexed keywords

2 HYDROXYMETHYLOLANZAPINE; CITALOPRAM; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; N NOROLANZAPINE; OLANZAPINE; SERTRALINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANOREXIA NERVOSA; BODY MASS; CHILD PSYCHIATRY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE FACTORS; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; PIRENZEPINE; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 33845686245     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000249950.75462.7f     Document Type: Conference Paper

References (37)

1. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137.
2. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
3. Kelly DL, Love RC, MacKowick M, et al. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol. 2004;14:75-85.
4. Remschmidt H, Hennighausen K, Clement HW, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2000;9(Suppl 1):I9-I19.
5. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry. 2004;65(Suppl 6):30-44.
6. Roerig JL, Mitchell JE, Steffen KJ. New targets in the treatment of anorexia nervosa. Expert Opin Ther Targets. 2005;9:135-151.
7. Mehler C, Wewetzer C, Schulze U, et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry. 2001;10:151-157.
8. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry. 2000;61(Suppl 8):26-30.
9. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
10. Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatric Res. 2001;35:339-345.
11. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.
12. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
13. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
14. Baumann P, Hiemke C, Ulrich S, et al. Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
15. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol. 2000;20:220-225.
16. Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12:83-91.
17. Theisen FM, Grabarkiewicz J, Fegbeutel C, et al. Olanzapine overdose in children and adolescents: two case reports and a review of the literature. J Child Adolesc Psychopharmacol. 2005;15:986-995.
18. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-526.
19. Schulz E, Fleischhaker C, Remschmidt H. Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry. 1995;28:20-25.
20. Clement HW, Fleischhaker C, Heger R, et al. Bestimmung von Olanzapin mit HPLC in Serumproben schizophrener Patienten. In: Kuss HJ, ed. Therapeutisches Drug Monitoring von Psychopharmaka: Labormethoden. Aachen: Shaker, 2001:114-122.
21. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit. 1999;21:87-90.
22. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens: when does therapeutic become toxic? J Forensic Sci. 2000;45:418-421.
23. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23:410-413.
24. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63-68.
25. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med. 1999;34:275-278.
26. Roland L, Cay A, Mats N, et al. Non-fatal overdose with high serum levels of olanzapine in a 36-year old male patient [Abstract]. Therapeutic Drug Monit. 2005;27:233.
27. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(Suppl 11):12-25.
28. Bachmann KA. Genotyping and phenotyping the cytochrome p-450 enzymes. Am J Ther. 2002;9:309-316.
29. Eli Lilly and Company. Product Information: Olanzapine: PV 3516 AMP. Indianapolis, IN: Eli Lilly and Company, 1997, 2005. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed March 30, 2006.
30. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65:766-771.
31. Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother. 2004;5:2287-2292.
32. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40:101-104.
33. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54:639-643.
34. Licht RW, Olesen OV, Friis P, et al. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol. 2000;20:110-112.
35. Xue L, Crookham SB, Diamond FX, et al. Development of a gas chromatographic method for the determination of olanzapine in human serum, and a report of patient values. Clin Chem. 1998;44:A103.
36. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997;17:472-477.
37. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20.